These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials. Nassif ME; Windsor SL; Gosch K; Borlaug BA; Husain M; Inzucchi SE; Kitzman DW; McGuire DK; Pitt B; Scirica BM; Shah SJ; Umpierrez G; Austin BA; Lamba S; Khumri T; Sharma K; Kosiborod MN Circ Heart Fail; 2023 Jul; 16(7):e009837. PubMed ID: 37203441 [TBL] [Abstract][Full Text] [Related]
5. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. Kosiborod MN; Bhatt AS; Claggett BL; Vaduganathan M; Kulac IJ; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Vardeny O; Lindholm D; Wilderäng U; Bengtsson O; McMurray JJV; Solomon SD J Am Coll Cardiol; 2023 Feb; 81(5):460-473. PubMed ID: 36526515 [TBL] [Abstract][Full Text] [Related]
6. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Tang F; Khariton Y; Malik AO; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Chandra L; Gordon RA; Ryan JJ; Chaudhry SP; Joseph SM; Chow CH; Kanwar MK; Pursley M; Siraj ES; Lewis GD; Clemson BS; Fong M; Kosiborod MN Nat Med; 2021 Nov; 27(11):1954-1960. PubMed ID: 34711976 [TBL] [Abstract][Full Text] [Related]
7. Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials. Gupta K; Spertus JA; Birmingham M; Gosch KL; Husain M; Kitzman DW; Pitt B; Shah SJ; Januzzi JL; Lingvay I; Butler J; Kosiborod M; Lanfear DE Circulation; 2023 Jul; 148(3):220-228. PubMed ID: 37191040 [TBL] [Abstract][Full Text] [Related]
8. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents. Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K; Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543 [TBL] [Abstract][Full Text] [Related]
9. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study. Carbone S; Billingsley HE; Canada JM; Bressi E; Rotelli B; Kadariya D; Dixon DL; Markley R; Trankle CR; Cooke R; Rao K; B Shah K; Medina de Chazal H; Chiabrando JG; Vecchié A; Dell M; L Mihalick V; Bogaev R; Hart L; Van Tassell BW; Arena R; Celi FS; Abbate A Diabetes Metab Res Rev; 2020 Nov; 36(8):e3335. PubMed ID: 32415802 [TBL] [Abstract][Full Text] [Related]
10. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD; JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043 [TBL] [Abstract][Full Text] [Related]
11. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Abraham WT; Lindenfeld J; Ponikowski P; Agostoni P; Butler J; Desai AS; Filippatos G; Gniot J; Fu M; Gullestad L; Howlett JG; Nicholls SJ; Redon J; Schenkenberger I; Silva-Cardoso J; Störk S; Krzysztof Wranicz J; Savarese G; Brueckmann M; Jamal W; Nordaby M; Peil B; Ritter I; Ustyugova A; Zeller C; Salsali A; Anker SD Eur Heart J; 2021 Feb; 42(6):700-710. PubMed ID: 33351892 [TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. Abraham WT; Ponikowski P; Brueckmann M; Zeller C; Macesic H; Peil B; Brun M; Ustyugova A; Jamal W; Salsali A; Lindenfeld J; Anker SD; Eur J Heart Fail; 2019 Jul; 21(7):932-942. PubMed ID: 31218819 [TBL] [Abstract][Full Text] [Related]
13. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500 [TBL] [Abstract][Full Text] [Related]
14. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240 [No Abstract] [Full Text] [Related]
15. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498 [TBL] [Abstract][Full Text] [Related]
16. Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure. Golbus JR; Gosch K; Birmingham MC; Butler J; Lingvay I; Lanfear DE; Abbate A; Kosiborod ML; Damaraju CV; Januzzi JL; Spertus J; Nallamothu BK JACC Heart Fail; 2023 Nov; 11(11):1521-1530. PubMed ID: 37498273 [TBL] [Abstract][Full Text] [Related]
17. Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Trial. Nassif M; Birmingham MC; Lanfear DE; Golbus JR; Gupta B; Fawcett C; Harrison MC; Spertus JA J Card Fail; 2023 Jun; 29(6):863-869. PubMed ID: 37040839 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831 [TBL] [Abstract][Full Text] [Related]